Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Prostate cancer

Targeting survivin in CRPC does not improve survival

Nature Reviews Urology volume 11, page 3 (2014)Cite this article

Subjects

Overexpression of survivin has been implicated in the development of castration-resistant prostate cancer (CRPC), leading investigators to evaluate the efficacy of survivin inhibitor LY2181308 sodium. This antisense oligonucleotide was given to patients with metastatic CRPC in combination with docetaxel plus prednisone in a phase II study. No differences in progression-free survival, overall survival or PSA response were found between men who received LY2181308 sodium and those who received docetaxel plus prednisone alone.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wiechno, P. et al. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur. Urol. 10.1016/j.eururo.2013.10.039

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Targeting survivin in CRPC does not improve survival. Nat Rev Urol 11, 3 (2014). https://doi.org/10.1038/nrurol.2013.280

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2013.280

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing